Jazz Pharmaceuticals plc (JAZZ) stock
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30119% above fair value
$241.55+1.18 (+0.49%)
Close on Nov 13, 2026Market cap $15.68BP/E 78.7Yield –
Jazz Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Jazz Pharmaceuticals's gross margin for the twelve months ending Dec 31, 2020 was 93.0%.
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2020 | Dec 31, 2020 | 91.8% | −1.2 |
| Q3 FY2020 | Sep 30, 2020 | 92.3% | −0.8 |
| Q2 FY2020 | Jun 30, 2020 | 94.3% | +1.5 |
| Q1 FY2020 | Mar 31, 2020 | 93.8% | +1.3 |
| Q4 FY2019 | Dec 31, 2019 | 93.0% | +0.5 |
| Q3 FY2019 | Sep 30, 2019 | 93.2% | −0.3 |
| Q2 FY2019 | Jun 30, 2019 | 92.8% | +0.6 |
| Q1 FY2019 | Mar 31, 2019 | 92.5% | +0.9 |
| Q4 FY2018 | Dec 31, 2018 | 92.6% | −0.2 |
| Q3 FY2018 | Sep 30, 2018 | 93.4% | +2.0 |
| Q2 FY2018 | Jun 30, 2018 | 92.2% | +0.7 |
| Q1 FY2018 | Mar 31, 2018 | 91.5% | −1.2 |
| Q4 FY2017 | Dec 31, 2017 | 92.8% | +2.3 |
| Q3 FY2017 | Sep 30, 2017 | 91.5% | – |
| Q2 FY2017 | Jun 30, 2017 | 91.5% | – |
| Q1 FY2017 | Mar 31, 2017 | 92.7% | – |
| Q4 FY2016 | Dec 31, 2016 | 90.5% | – |
See a number that looks wrong?